FDA drug development initiative
Executive Summary
FDA's initiative to accelerate development of new drugs will be a topic of the agency's Science Board meeting on April 22. The "Critical Path" initiative will redirect research funding towards identifying major barriers to drug development (1"The Pink Sheet" March 22, 2004, p. 30)...
You may also be interested in...
FDA Will Fund Research On “Critical Path” Of Drug Development
FDA's "Critical Path" initiative will redirect the agency's research funding towards identifying and alleviating some major barriers to drug development
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.